title: Spread of Staphylococcus aureus in hospitals: causes and prevention.
abstract: Methicillin-resistant Staphylococcus aureus (MRSA) has become a major nosocomial pathogen in many hospitals worldwide. Even more alarming, MRSA strains that are vancomycin intermediate-susceptible are isolated with increasing frequency, making therapy for staphylococcal infections even more difficult and prevention more important than ever. Spread of S. aureus in hospitals and infection control measures are reviewed. The major sources of S. aureus in hospitals are septic lesions and carriage sites of patients and personnel. Carriage often precedes infection. The anterior nares are the most consistent carriage site, followed by the perineal area. Skin contamination and aerial dissemination vary markedly between carriers and are most pronounced for combined nasal and perineal carriers. The principal mode of transmission is via transiently contaminated hands of hospital personnel. Airborne transmission seems important in the acquisition of nasal carriage. Infection control strategies include screening and isolation of newly admitted patients suspected of carrying MRSA or S. aureus with intermediáte resistance to vancomycin, implementation of an infection control program to prevent transmission of resistant strains between patients and hospital personnel, and institution of a proper antibiotic policy to minimize antibiotic resistance development. MRSA carriers should be treated with intranasal antibiotics, e.g. mupirocin, and skin disinfectants to eliminate carriage. Education of hospital personnel is essential. Improved knowledge about the best ways to ensure favourable infection control practices is needed. Active intervention against the spread of MRSA is important.
authors.affiliation: Department of Medicine, Haukeland Hospital, Bergen, Norway.
authors.forename: C O
authors.initials: CO
authors.lastname: Solberg
mesh_terms: D002353:Carrier State / Q000188:drug therapy / Q000517:prevention & control / Q000635:transmission*; D003362:Cost-Benefit Analysis; D003428:Cross Infection / Q000188:drug therapy / Q000517:prevention & control / Q000635:transmission*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D017053:Infection Control / Q000191:economics; D016106:Methicillin Resistance; D009666:Nose / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000517:prevention & control / Q000635:transmission*; D013211:Staphylococcus aureus / Q000187:drug effects*; D020713:Vancomycin Resistance